Action on Hearing Loss Logo
    Total results:
    Search
      Total results:

      Finding treatments faster

      In March, Action on Hearing Loss gathered experts from across the world to discuss ways to accelerate the development of treatments for hearing disorders.

      TRIH Summit 2018

      According to a recent report from the World Health Organization, 466 million people in the world have disabling hearing loss and 1.1 billion young people (12-35 years old) are at risk of losing their hearing due to recreational noise (WHO, 2018).

      As the world’s largest, donor-funded research programme dedicated to finding treatments for hearing loss and tinnitus, the biomedical research team at Action on Hearing Loss teamed up with the University College London (UCL) Ear Institute and the National Institute for Health Research (NIHR) to gather 159 experts in hearing loss from across the world at a summit in London, on the 22nd March. We invited experts from universities, biotechnology and pharmaceutical companies, investors, commissioners, clinicians and patients to talk about the biggest challenges and opportunities in hearing loss research and discuss how to speed up the development of treatments for hearing loss and tinnitus.

      At the summit, the attendees heard about the latest exciting developments in research and clinical trials. Highlights included Novartis, one of the largest pharmaceutical companies in the world, sharing the progression of a gene therapy to regenerate hearing that Novartis is currently testing in people. Fennec Pharmaceuticals presented the successful results of their Phase 3 trial, the last stage of testing in people before being licensed to be used in the clinic. Fennec has shown that their therapy successfully protects the hearing of children who undergo chemotherapy treatments with drugs that damage the cells in the inner ear.

      16 companies and researchers from around the world presented their work focussing on the development of different treatments to protect or regenerate hearing. The summit ended with a round table discussion between eight experts and the audience in the room about how can we all contribute to speed up the development of treatments for hearing disorders.

      Find out more

      We depend on your donations so we can fund the best hearing and tinnitus research around the world. Donate today and help us continue our vital work into hearing treatments, so that people can live life to the full again.

      If you want to have a sneak peek at the summit and hear the opinion of Dr Steven Holtzman, President & CEO of Decibel Therapeutics, a US-based company developing treatments for different forms of hearing loss; Hugh Strickland, Corporate Finance Partner at Aaron & Partners, who has hereditary hearing loss, and Dr Ralph Holme, Executive Director of Research at Action on Hearing Loss, watch the summit highlights

      A specialized report that summarizes the discussions of the day and proposes some of the changes that need to be implemented to accelerate the development of treatments can be found on the same page on the right hand side.

      By: Dr Tracey Pollard | 14 June 2018

      Summit Report

      Download the report of the summit.

      Download

      Recent Posts

      EE partnership brings unbeatable packages

      For the first time ever, selected mobile phones with EE Pay As You Go plans, tailored for people who are deaf or have hearing loss, are available from Action on Hearing Loss.

      By: Brian Burns
      17 October 2018

      REGAIN update on the progress so far and a further opportunity for people with hearing loss to take part in the trial

      A team of researchers and clinicians at UCL’s Ear Institute and the Royal National Throat Nose and Ear Hospital are delighted to announce that the REGAIN trial is approaching its first anniversary and are continuing to recruit people with hearing loss to participate in a ground breaking clinical trial to test the safety and efficacy of a new drug that aims to treat sensorineural hearing loss. The criteria for eligibility to participate in the trial has recently been broadened to include participants with hearing loss of up to 20 years duration (see below for further information).

      By: REGAIN
      16 October 2018

      Preventing hearing loss: the search for treatments

      Medicines like aminoglycoside antibiotics or cisplatin are used to combat life-threatening infections and cancer, respectively, but their use may come at the price of someone’s hearing. Several treatments to prevent the loss of hearing caused by these medicines are currently being developed. Our Translational Research Manager, Dr Carina Santos, tells us more.

      By: Dr Carina Santos
      12 October 2018

      Shining a light on the cochlea

      We fund research across the globe into treatments for hearing loss and tinnitus. One of our newest projects, at the Bionics Institute in Australia, is investigating if we can improve how well cochlear implants work using light.

      By: Dr Tracey Pollard
      11 October 2018

      Recent Posts

      EE partnership brings unbeatable packages

      For the first time ever, selected mobile phones with EE Pay As You Go plans, tailored for people who are deaf or have hearing loss, are available from Action on Hearing Loss.

      By: Brian Burns
      17 October 2018

      REGAIN update on the progress so far and a further opportunity for people with hearing loss to take part in the trial

      A team of researchers and clinicians at UCL’s Ear Institute and the Royal National Throat Nose and Ear Hospital are delighted to announce that the REGAIN trial is approaching its first anniversary and are continuing to recruit people with hearing loss to participate in a ground breaking clinical trial to test the safety and efficacy of a new drug that aims to treat sensorineural hearing loss. The criteria for eligibility to participate in the trial has recently been broadened to include participants with hearing loss of up to 20 years duration (see below for further information).

      By: REGAIN
      16 October 2018

      Preventing hearing loss: the search for treatments

      Medicines like aminoglycoside antibiotics or cisplatin are used to combat life-threatening infections and cancer, respectively, but their use may come at the price of someone’s hearing. Several treatments to prevent the loss of hearing caused by these medicines are currently being developed. Our Translational Research Manager, Dr Carina Santos, tells us more.

      By: Dr Carina Santos
      12 October 2018

      Shining a light on the cochlea

      We fund research across the globe into treatments for hearing loss and tinnitus. One of our newest projects, at the Bionics Institute in Australia, is investigating if we can improve how well cochlear implants work using light.

      By: Dr Tracey Pollard
      11 October 2018

      More like this

      We're really proud of everyone who's a part of Action on Hearing Loss, and hope you'll feel inspired to become a part of our community.​

      We campaign for changes that make life better for people who are confronting deafness, tinnitus and hearing loss.

      Our ears are our organs of hearing and balance. They have three parts: the outer, middle and inner ear.